Although originally developed for diabetes management, Semaglutide is gaining more attention for its effect on weight loss
We look forward to seeing your progress.
Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors
If youre close to your goal and weight loss is still active, even slowly, staying at the current dose is often the right call
Patients should report any signs such as trouble swallowing or severe stomach pain, which may indicate underlying complications
We have already made the products for testing but cannot launch until patent expiration," GV Prasad, co-chairman and managing director, Dr Reddy's said.The company is strategically targeting markets where patents expire earliest, with India's launch timeline slightly later than Canada and Brazil, he indicated at the Nasscom GCC Summit here.The Hyderabad-based pharma major is looking at a portfolio of around 15 GLP-1 drugs that are used to treat diabetes and obesity, which it plans to roll out at various points in time based on patent expiry in different markets globally.He also highlighted the need for both innovator companies and generic manufacturers in the pharmaceutical industry